CoVIg-19 / Takeda - LARVOL DELTA

Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval (Reuters) - "The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing....The trial will test the hyperimmune globulin therapy in combination with Gilead Sciences Inc's GILD.O antiviral drug remdesivir compared with patients who get remdesivir alone, he said....The alliance does not intend to profit from the treatment, Weber said."

Clinical • Infectious Disease • Novel Coronavirus Disease

Takeda announces results for the first quarter of fiscal 2020; confirms the executive's guidance and increases the operating profit and net profit indicated for the full year [Google translation] (Businesswire) - "CoVIg-19 is expected to start a registry enabling study in patients with COVID-19 in the coming weeks....The CoVIg-19 Plasma Alliance continued the development of a potential unmarked hyperimmune globulin (H-Ig) research treatment for COVID-19. Manufacturing of the first batch of CoVIg-19 started at Takeda's manufacturing site in Georgia, USA, in May, and is ready to be shipped to study centers."

Commercial • New trial • Infectious Disease • Novel Coronavirus Disease

"^ Research TAK-888 @TakedaPharma" (@SURGDissection)

Biopharma's leading treatment hopes against COVID-19 (FierceBiotech) - "The Japanese Big Pharma is working on an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, which it's calling TAK-888....'We’re collaborating with several health and regulatory agencies and health care partners across the globe to move the research forward.'"

Clinical

Takeda begins development of plasma-derived therapy for covid-19 [Google translation] (News Farma) - "Takeda has started the development of a polyclonal hyperimmune anti-SARS-CoV-2 (H-IG) globulin to treat high-risk people with covid-19, while it is studying whether the drugs it currently markets could be effective for infected patients....Takeda is in talks with several national health and regulatory agencies, as well as healthcare partners in the United States of America (USA), Asia and Europe to rapidly advance TAK-888 research."

Clinical

"TAK-888 https://t.co/yIdwF6wJTy" (@dmohanmd)